Tumor Profiling Market Report 2026

Tumor Profiling Market Overview

• Tumor Profiling market size has reached to $11.18 billion in 2025 • Expected to grow to $17.96 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Growing Adoption Of Personalized Medicine Fueling the Growth Of The Market Due To Increasing Demand For Targeted And Effective Cancer Therapies • Market Trend: Artificial Intelligence (AI)-Powered Diagnostic Innovations Driving Growth In The Market Through Enhanced Precision And Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tumor Profiling Market?

Tumor profiling refers to a set of techniques used to analyze and characterize the genetic and molecular features of a tumor, which helps to identify specific mutations, gene expression patterns, and other molecular characteristics of cancer cells, and this tumor profiling can provide crucial information about the biology of a particular tumor, guide treatment decisions, and inform personalized therapies. The main techniques of tumor profiling are genomics, proteomics, epigenetics, and metabolomics. Genomics refers to the study of the genetic material (DNA) of cancer cells to understand the genetic changes that contribute to the formation and progression of tumors. It utilizes technologies such as sequencing techniques, quantitative polymerase chain reaction (qPCR), immunohistochemistry, in situ hybridization (ISH), and microarray, and these are applied in areas such as personalized cancer medicine, oncological diagnostics, and research.

What Is The Tumor Profiling Market Growth Forecast?

The tumor profiling market size is expected to see strong growth in the next few years. It will grow to $17.96 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing adoption of precision oncology, growing demand for personalized cancer treatment, advancements in bioinformatics platforms, expansion of companion diagnostics, rising investments in translational cancer research. Major trends in the forecast period include increasing adoption of next-generation sequencing, rising use of multi-omics profiling approaches, growing integration of AI-based data interpretation, expansion of personalized oncology applications, enhanced focus on biomarker discovery.

Global Tumor Profiling Market Segmentation

1) By Technique: Genomics, Proteomics, Epigenetics, Metabolomics 2) By Technology: Sequencing Techniques, Quantitative Polymerase Chain Reaction (qPCR), Immunohistochemistry, In Situ Hybridization (ISH), Microarray 3) By Application: Personalized Cancer Medicine, Oncological Diagnostics, Research Subsegments: 1) By Genomics: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarrays, Sanger sequencing 2) By Proteomics: Mass Spectrometry (MS), Protein Microarrays, Immunohistochemistry (IHC), Western Blotting 3) By Epigenetics: DNA Methylation Analysis, Chromatin Immunoprecipitation Sequencing (ChIP-seq), Histone Modification Profiling, Non-Coding RNA Analysis 4) By Metabolomics: Nuclear Magnetic Resonance (NMR) Spectroscopy, Gas Chromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-Mass Spectrometry (LC-MS), Capillary Electrophoresis-Mass Spectrometry (CE-MS)

What Is The Driver Of The Tumor Profiling Market?

The rise in demand for personalized medicine is expected to drive the growth of the tumor profiling market going forward. Personalized medicine refers to an approach that tailors healthcare treatments to the individual characteristics of each patient. This increase is driven by patients seeking more precise therapies that offer better outcomes and fewer side effects compared to traditional treatments. The tumor profiling is helping personalized medicine by identifying specific genetic mutations and biomarkers in a patient's tumor, enabling targeted treatments and reducing side effects. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition, a US-based organization dedicated to advancing personalized medicine, personalized medicines accounted for more than one-third of all new drug approvals in 2023, marking the fourth consecutive year of this trend. Therefore, the growing demand for personalized medicine is driving growth in the tumor profiling industry.

Key Players In The Global Tumor Profiling Market

Major companies operating in the tumor profiling market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., GenScript Biotech Corporation, NeoGenomics Inc., Caris Life Sciences Inc., Tempus Inc., Foundation Medicine Inc., NanoString Technologies Inc., Personalis Inc., Boreal Genomics Inc., Strand Life Sciences Pvt. Ltd., HTG Molecular Diagnostics Inc., Lucence Health Inc., Predictive Oncology Inc.

Global Tumor Profiling Market Trends and Insights

Major companies operating in the tumor profiling market are focusing on developing advanced solutions, such as artificial intelligence (AI)-powered diagnostic solutions, to enhance accuracy and efficiency in cancer treatment. Artificial intelligence (AI) refers to the use of advanced computational methods to analyze complex genomic, proteomic, and clinical data, enabling faster diagnoses, personalized treatment strategies, and better monitoring of disease progression. For instance, in January 2025, Panakeia Technologies LTD, a UK-based company specializing in AI-driven software for cancer diagnosis and treatment, launched PANProfiler Colon, an AI-driven software solution specifically designed to profile key molecular biomarkers such as microsatellite instability (MSI) and mismatch repair deficiency (dMMR) from H and E-stained images of colon cancer tissue samples. This digital tool enables rapid and accurate molecular profiling of tumors, which is essential for diagnosing colorectal cancer, identifying cases of Lynch syndrome, and informing personalized treatment decisions.

What Are Latest Mergers And Acquisitions In The Tumor Profiling Market?

In February 2024, Myriad Genetics Inc., a US-based provider of genetic testing and precision medicine, acquired assets from Intermountain Precision Genomics (IPG) for an undisclosed amount. Through this acquisition, Myriad strengthens its precision oncology portfolio by adding the precise tumor test, the precise liquid test, and IPG’s CLIA-certified laboratory in St. George, Utah, to advance patient care. Intermountain Precision Genomics is a US-based molecular diagnostics division that focuses on genomic testing and tumor profiling.

Regional Outlook

North America was the largest region in the tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tumor Profiling Market?

The tumor profiling market includes revenues earned by entities by providing services such as biomarker testing, methylation profiling, and clinical trial matching. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor profiling market also includes sales of liquid biopsy kits, immunohistochemistry (IHC) kits, and methylation profiling kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tumor Profiling Market Report 2026?

The tumor profiling market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tumor profiling industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.